Technology evaluation: epratuzumab, Immunomedics/Amgen.
Immunomedics and Amgen are developing the unconjugated form of the anti-CD22 humanized monoclonal antibody, epratuzumab, for the potential treatment of lymphoma, non-Hodgkin's lymphoma (NHL) and certain autoimmune conditions. Immunogenics is also developing the radioisotope-linked (90Y) form of epratuzumab. The monoclonal antibody is currently undergoing phase III clinical trials for the potential treatment of aggressive lymphoma. By January 2003, epratuzumab had received Orphan Drug status in the US for its potential in the treatment of NHL.
Juweid
Malik
M
Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. malik-juweid@uiowa.edu
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D001327:Autoimmune Diseases / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C448700:epratuzumab